Can your doctor prescribe MOTS-c to help you lose weight? A federal enforcement policy cleared White House review on October 27, 2026, and under HHS's policy text, pharmacies could compound MOTS-c under its conditions once it is issued. Readers should confirm the effective date and final text in the Federal Register. That policy lasts only until FDA finishes a final rule on the peptide, and MOTS-c is not FDA-approved.
The policy does not let doctors prescribe these at their own discretion. The federal compounding statute ties compounding to a valid prescription order for an identified patient, and the policy addresses whether a peptide is eligible as a bulk drug substance. Under the policy, HHS says it does not intend to take enforcement action against a pharmacy that compounds MOTS-c when all conditions are met, once the policy is issued.
What did the federal policy change for MOTS-c?
The Department of Health and Human Services wrote an HHS peptide enforcement policy whose text lists six peptides in Appendix A. MOTS-c is one of them. The policy had cleared White House review but was not yet published when this article was researched. For each listed peptide, HHS says it does not intend to act against a state-licensed pharmacy, a Federal facility or a licensed physician who compounds it, as long as every condition is met.
This is enforcement discretion, not approval. The policy states that “Compounded drugs are not FDA-approved.” A law firm analysis, Legal 500, adds that a statement that FDA does not intend to pursue certain violations “would not amend the statute or constitute approval of a compounded drug.”
The policy text carries no date. The White House review office lists its review as completed on October 27, 2026, with the conclusion “Consistent with Change,” in its OIRA review record. Check the Federal Register for the final text before you rely on any detail here.
What conditions must be met?
The policy covers MOTS-c only when every one of these conditions is present.
| Condition | What the policy requires |
|---|---|
| Prescription | A valid patient-specific prescription for an identified patient. |
| Who compounds | A state-licensed pharmacy, a Federal facility or a licensed physician. |
| Ingredient | MOTS-c from an original manufacturer registered with FDA under section 510, with a valid certificate of analysis. |
| Single ingredient | The product contains only one active ingredient from the list. |
| Route | Subcutaneous or intramuscular injection only. |
| Device | The only device is an FDA 510(k)-cleared syringe. |
| Label | “This is a compounded drug product. Not for resale.” |
| Reporting | Serious adverse events and quality problems are reported to FDA's MedWatch and to the states. |
A research-use-only vial is not covered by this policy. HHS says the policy is meant to discourage research-use-only peptides from foreign manufacturers, and it pairs that with a controlled alternative for compounding. If a seller offers MOTS-c without a prescription from a licensed prescriber and a licensed pharmacy, the policy does not apply to it.
What does the research show about MOTS-c and weight?
Most of the MOTS-c research is about how cells and animals use energy. Human evidence for MOTS-c on weight is thin.
A 2023 Frontiers bone-metabolism review describes MOTS-c as a mitochondrial-derived peptide involved in energy metabolism.
HHS's justification for the policy points to rodent studies that reported metabolic benefit without systemic toxicity. It also cites a randomized placebo-controlled trial of a MOTS-c analogue, which reported no serious adverse events at an exposure well above the compounded regimen. An analogue is a related molecule, not MOTS-c itself.
Why was MOTS-c on the list, and how did the vote go?
MOTS-c was in FDA's category 2 from September 29, 2023 until April 22, 2026, according to the policy's Appendix B. In July 2026, an FDA advisory committee narrowly voted to recommend adding it and five other peptides to the compounding list. ABC News notes that the vote is non-binding and still needs FDA sign-off. The Hill reports that FDA's own staff concluded there was not enough evidence to support adding any of the six.
Not everyone agrees. The Partnership for Safe Medicines petition filed October 16, 2026 asks FDA not to allow compounding of six peptides it names (BPC-157, KPV, TB-500, MOTS-c, emideltide and semax), and MOTS-c is one of them. According to ABC News, the committee recommended Epitalon rather than emideltide, and it rejected emideltide.
Can MOTS-c make you tired?
FDA's FDA bulk substance safety risk list, current as of 04/22/2026, says FDA “has not identified any human exposure data on drug products containing MOTs-C administered via any route of administration.” It also says “FDA lacks important information regarding any safety issues raised by MOTs-C.” If you notice new tiredness on any medicine, tell your prescriber.
Is it safe to take MOTS-c twice a week?
The policy sets the allowed route, which is subcutaneous or intramuscular injection. It does not set how often you would take it. The schedule is a decision for your prescriber, not something to copy from an online post. FDA says it lacks the information to know whether MOTS-c would cause harm if administered to humans.
Can you take MOTS-c with retatrutide?
Retatrutide is not on the policy's list of six peptides, so the policy does not cover it. Each compounded product may contain only one active ingredient, so the policy does not describe a combined product. Ask your prescriber whether any combination makes sense for you.
Is MOTS-c better than retatrutide, or the strongest peptide for weight loss?
The HHS policy does not compare MOTS-c with retatrutide, and it does not rank any peptide for weight loss. The AP report on the policy says the peptides at issue “haven't gone through that rigorous vetting process.” ABC News describes some GLP-1 medicines as FDA-approved medicines that have been rigorously tested.
Can peptides help with weight loss?
“Peptide” covers many different molecules. The HHS policy covers six, and it sets the identity and allowed route for each one. It does not show a weight-loss use for any of them.
| Peptide on the policy list | Routes the policy allows |
|---|---|
| BPC-157 | Subcutaneous, intramuscular, oral and topical |
| Epitalon | Subcutaneous or intramuscular injection, in intermittent courses |
| KPV | Topical and oral only |
| MOTS-c | Subcutaneous or intramuscular injection |
| Semax | Intranasal only |
| TB-500 | Subcutaneous or intramuscular injection |
Is NAD better than MOTS-c, or can myo-inositol help?
The HHS policy does not mention NAD or myo-inositol. Neither is one of the six peptides. For a broader look at supplements, see weight loss supplements. For the weight-loss evidence on a specific ingredient, ask your prescriber or a pharmacist.
Is MOTS-c really worth it for weight loss?
The research on MOTS-c is interesting, especially on how cells use energy. MOTS-c is worth a serious conversation with a prescriber who knows your health history. Keep the FDA-approved options in the same conversation.
What are the FDA-approved options for weight loss?
FDA-approved weight-loss medicines exist, and ABC News describes GLP-1 medicines as FDA-approved medicines that have been rigorously tested. Your prescriber can lay them out next to MOTS-c. Lifestyle changes also belong in the plan. Your guide to healthy weight loss covers the basics. If you have tried fast fixes before, why quick fixes don't work explains why steady changes tend to last longer.
Questions to ask your prescriber or pharmacy
- Will a licensed pharmacy in my state compound MOTS-c under this policy, and which conditions will it follow?
- Will the product be labeled “This is a compounded drug product. Not for resale.”?
- Can I see the certificate of analysis for the ingredient?
- Which FDA-approved weight-loss options fit my health history, and how do they compare with MOTS-c?
- What side effects should I report, and who do I report them to?
Your next step is small. Book one visit with a prescriber, bring a list of your current medicines, and ask these questions before you decide.
By the Gym Floor Guide Editorial Team
This article is for general information purposes only and does not constitute medical advice. Consult your doctor or qualified healthcare provider before making changes to your health routine.